GlassScriptPhysician profile
Deborah A Mcelroy
NPI 1275952665
$3,504.70
in general payments reported to CMS, 2019-2025
24 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $543 · 2023: $673 · 2024: $1,113 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,841.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $366.54 | 2024-2025 | Cabenuva |
| Amgen INC. | $349.78 | 2024-2025 | Krystexxa |
| Genzyme Corporation | $277.84 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $206.28 | 2024-2025 | |
| Abbvie INC. | $165.16 | 2022-2023 | |
| Abbott Laboratories | $153.43 | 2024 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $139.51 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $134.99 | 2025 | Austedo Xr |
| Neurelis, INC. | $125.00 | 2024 | Valtoco |
| Emd Serono, INC. | $124.72 | 2023 | Serostim |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Lexicon Pharmaceuticals, INC. | $121.81 | 2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $120.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.83 | 2022 | |
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $111.36 | 2022 | |
| Glaxosmithkline, LLC. | $111.12 | 2024 | Shingrix |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
| Kowa Pharmaceuticals America, INC. | $94.69 | 2022 | |
| Braeburn INC. | $91.16 | 2024 | Brixadi |
| Novo Nordisk INC | $87.03 | 2022 | |
| Theratechnologies INC. | $86.97 | 2025 | Egrifta |
| Medtronic, INC. | $71.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.